Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 139631-62-2 Chemical Structure| 139631-62-2

Structure of Cyclopropanesulfonyl chloride
CAS No.: 139631-62-2

Chemical Structure| 139631-62-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 139631-62-2 ]

CAS No. :139631-62-2
Formula : C3H5ClO2S
M.W : 140.59
SMILES Code : O=S(C1CC1)(Cl)=O
MDL No. :MFCD01631933
InChI Key :PFWWSGFPICCWGU-UHFFFAOYSA-N
Pubchem ID :2760919

Safety of [ 139631-62-2 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H314
Precautionary Statements:P280-P305+P351+P338-P310
Class:8
UN#:3265
Packing Group:

Computational Chemistry of [ 139631-62-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 7
Num. arom. heavy atoms 0
Fraction Csp3 1.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 28.18
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

42.52 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.27
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.94
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.74
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.01
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.81
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.95

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.24
Solubility 8.13 mg/ml ; 0.0578 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.42
Solubility 5.35 mg/ml ; 0.0381 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.99
Solubility 14.3 mg/ml ; 0.101 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.49 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.33

Application In Synthesis of [ 139631-62-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 139631-62-2 ]

[ 139631-62-2 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 139631-62-2 ]
  • [ 154350-29-5 ]
YieldReaction ConditionsOperation in experiment
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; for 24h;Product distribution / selectivity; II. Preparation of P1' Intermediates 1. Preparation of Cyclopropylsulfonamide Method 1 (of 2): To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to provide 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01. Anal. Calcd. For C3H7NO2S: C, 29.74; H, 5.82; N, 11.56. Found: C, 29.99; H, 5.89, N, 11.50.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF. The solution was warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained and poured onto a 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to provide 3.45 g (100%) of cyclopropylsulfonamide as a white solid. 1H NMR (methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; To a solution of 100 mL of THF cooled to 0 C was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g(28. 45 mmol) of cyclopropylsulfonyl chloride (purchased from ArrayBiopharma) in 50mL of THF, the solution warmed to rtovernite and stirred one additional day. The mixture was concentrated until 1-2mL of solvent remained, applied onto 30 g plug ofSi02 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45g (100%) of cyclopropyl sulfonamide as a whitesolid.'H NMR (Methanol-d4) 0.94-1. 07 (m, 4H), 2.52-2. 60 (m,1H); 13C NMR(methanol-d4)8 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; Method A: To a solution of 100 mL of TUF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied onto 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropylsulfonamide as a white solid.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 C was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied onto 30 g plug of Si02 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3. 45g (100%) of cyclopropyl sulfonamide as a white solid NMR (Methanol-d4) 8 0.94-1. 07 (m, 4H), 2.52-2. 60 (m, 1H) ; 13C NMR (methanol-d4) 8 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 20℃;Product distribution / selectivity; Method A:; O NH3 ( sat ) THF O^ ^ -S I l -Cl „ n _ h I ^ S -NHO 0 0C to rt OTo a solution of 100 mL of THF cooled to 0 0C was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol^) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, IH); 13C NMR (methanol^) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; for 24h;Product distribution / selectivity; Method A To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to it overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃; To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; Method 2 To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF. The solution was warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained and poured onto a 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to provide 3.45 g (100%) of cyclopropylsulfonamide as a white solid. 1H NMR (methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
100% With ammonia; In tetrahydrofuran; at 0 - 20℃;Product distribution / selectivity; To a solution of 100 mL of THF cooled to 0 0C was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied on to 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol^) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, IH); 13C NMR (methanol^) δ 5.92, 33.01.
95% With ammonia; In dichloromethane; at -78 - 20℃; for 3.25h; Example 27Synthesis of new sulfonamides[0529] Preparation of compound 3: compound 1 (1Og, 71mmol) was dissolved in dry DCM (150ml) under nitrogen. The resulting solution was bubbled through NH3 for 15 minutes at -78 -C, then it was allowed to rise to room temperature and stirred for 3 h. Before filtration, the Filtrate was concentrated to provide compound 2 as white solid 8.2 g (yield
> 90% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Cyclopropylsulfonyl chloride (5 g, 35.56 mmol) was dissolved in 0.5 M ammonia in dioxane (200 ml, 100 mmol) at RT. The reaction was stirred at RT for 3 days. The large amount of precipitation was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 hours to give the cyclopropylsulfonamide (>90%). 1H-NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (1H, m), 1.20 (2H, m), 1.02 (2H, m).
89% With ammonia; In tetrahydrofuran; at 0 - 20℃; for 17h; Ammonia gas was bubbled through THF (355 mL) at 0 C. for 20 min. Neat cyclopropylsulfonyl chloride (1a, 15 g, 0.11 mol) was dropwise added to the solution. The resulting solution was allowed to warm to room temperature and stirred for 17 h. The resulting suspension was filtered through a plug of silica gel, eluting with ethyl acetate. The filtrate was concentrated in vacuo to afford 11.5 g (89%) of cyclopropylsulfonamide 1b. 1H NMR (300 MHz, CD3OD): δ 2.63-2.53 (m, 1H), 1.09-0.95 (m, 4H).
87% With ammonia; In tetrahydrofuran; at 0 - 20℃; [00279] Ammonia gas was bubbled through a gas dispersion tube into THF (40 mL) cooled to 0 0C for 5 minutes. To this solution at 0 0C was added cyclopropylsulfonylchloride (1 gram, 7.1 mmol). The reaction was stirred at room temperature overnight, then filtered through a plug of silica gel, followed by elution with EtOAc to yield 750 mg (6.19 mmol, EPO <DP n="294"/>87%) of cyclopropylsulfonamide. 1H-NMR (500 MHz, Methanol-d4): 4.79 (s, 2H), 2.59-2.54 (m, IH), 1.06-0.96 (m, 4H).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Example 46 Compound of Formula IV, wherein Step 46a: Cyclopropylsulfonyl chloride (1.4 g, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at RT. The reaction was kept at RT for 3 days. The large amount of precipitation was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 hours to give the cyclopropylsulfonamide (0.88 g, 74%). 1H-NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (1H, m), 1.20 (2H, m), 1.02 (2H, m).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Cyclopropylsulfonyl chloride (1.4g, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at rt. The reaction was stirred at rt for 72 h. The precipitate was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 h to give cyclopropylsulfonamide (0.88 g, 74%).1H NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (IH, m), 1.20 (2H, m), 1.02 (2H, m).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Cyclopropylsulfonyl chloride (1.4g, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at rt. The reaction was stirred at rt for 72 h. The precipitate was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 h to give cyclopropylsulfonamide (0.88 g, 74%).1H NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (IH, m), 1.20 (2H, m), 1.02 (2H, m).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Cyclopropylsulfonyl chloride (1.4 g, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at RT. The reaction was kept at RT for 3 days. The large amount of precipitation was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 hours to give the cyclopropylsulfonamide (0.88 g, 74%). 1H-NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (1H, m), 1.20 (2H, m), 1.02 (2H, m).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Cyclopropylsulfonyl chloride (IAg, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at RT. The reaction was kept at RT for 3 days. The large amount of precipitation was filtered and discarded. The clear filtrate was evaporated in vacuo and the white residue was dried on vacuum for 24 hours to give the cyclopropylsulfonamide (0.88 g, 74%). 1H- NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (IH, m), 1.20 (2H, m), 1.02 (2H, m).
74% With ammonia; In 1,4-dioxane; at 20℃; for 72h; Step 3A: Cyclopropylsulfonyl chloride (1.4g, 10 mmol) was dissolved in 0.5 M ammonia in dioxane (50 ml, 25 mmol) at RT. The reaction was kept at RT for 3 days. The large amount of precipitation was filtered and discarded. The clear filtrate was <n="44"/>evaporated in vacuo and the white residue was dried on vacuum for 24 hours to give the cyclopropylsulfonamide (0.88 g, 74%). 1H-NMR (500 MHz, CD3Cl): δ 4.62 (2H, s), 2.59 (IH, m), 1.20 (2H, m), 1.02 (2H, m).
52% With ammonium hydroxide; In methanol; at 20℃; for 16h; General procedure: Standard Procedure D for the Preparation of Sulfonamides (0054) A solution of sulfonyl chloride in methanol and ammonium hydroxide solution was stirred at 0 C. or room temperature. After the reaction was complete, methanol was removed under reduced pressure. The solution was extracted with ethyl acetate. The combined organic layers were dried over MgSO4(s), filtered, and concentrated to give the desired products without further purification. Step 1. Cyclopropanesulfonamide Following standard procedure D, cyclopropanesulfonyl chloride (0.400 mL, 3.95 mmol), methanol (3.0 mL), and ammonium hydroxide solution (15 mL) were used to carry out the reaction. After the reaction was stirred at room temperature for 16 h and work up, cyclopropanesulfonamide (0.249 g, 52%) was obtained as a white solid. 1H NMR (DMSO-d6, 300 MHz) δ 6.78 (br s, 2H), 2.50-2.46 (m, 1H), 0.89-0.86 (m, 4H).
3.45 g (100%) In tetrahydrofuran; ammonia; Preparation of cyclopropyl sulfonamide To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF, the solution warmed to rt overnite and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained, applied onto 30 g plug of SiO2 (eluted with 30% to 60% EtOAc/Hexanes) to afford 3.45 g (100%) of cyclopropyl sulfonamide as a white solid. 1H NMR (Methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
1.70 g (99%) In tetrahydrofuran; ammonia; Preparation of Cyclopropyl Sulfonamide Moiety for Use in Step 2e: To a solution of 20 mL THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added 2 g (5.69 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma). The solution was warmed to room temperature over two hours and the crude solution was filtered through a plug of silica gel eluding the product with ethyl acetate. The fractions were concentrated in vacuo to yield 1.70 g (99%) of cyclopropyl sulfonamide as a white solid: 1H NMR (d4-MeOH, 500 MHz) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H).
3.45 g (100%) In tetrahydrofuran; ammonia; Method 2 To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5 g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF. The solution was warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained and poured onto a 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to provide 3.45 g (100%) of cyclopropylsulfonamide as a white solid. 1H NMR (methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
3.45 g (100%) In tetrahydrofuran; ammonia; Method 2 To a solution of 100 mL of THF cooled to 0 C. was bubbled in gaseous ammonia until saturation was reached. To this solution was added a solution of 5g (28.45 mmol) of cyclopropylsulfonyl chloride (purchased from Array Biopharma) in 50 mL of THF. The solution was warmed to room temperature overnight and stirred one additional day. The mixture was concentrated until 1-2 mL of solvent remained and poured onto a 30 g plug of SiO2 (eluted with 30% to 60% ethyl acetate/hexanes) to provide 3.45 g (100%) of cyclopropylsulfonamide as a white solid. 1H NMR (methanol-d4) δ 0.94-1.07 (m, 4H), 2.52-2.60 (m, 1H); 13C NMR (methanol-d4) δ 5.92, 33.01.
With ammonia; In dichloromethane; at 0 - 20℃; To a solution of cyclopropylmagnesium bromide (0 5 M 20 mL, 10 0 mmol) in anhydrous THF (10 mL) at about -100C is added a solution of SO; in THF (~ 16 wt%, 4 8 mL, 12 mmo.) slowiy over 10 mm at -10 to -5C Tne reaction mixture is warmed to ambient temperature over 0 5h, and then NCS (2 O g 15 mmo.) is added at about -5 to 0C The reaction mixture is warmed up to ambient temperature and diluted with 50 mL oi methyl terl-buty. ether To tne reaction mixture ι≤ added 50 mL water and the mixture is stirred for 5 mm The organic layer is washed with 50 mL of bnne The organic layer is concentrated and the resultant cyclopropylsuifony. chloride is dissolved in CH2Ci2 (total volume was about 50 mL) and ammonia gas is bubbled in at about O'C for about 5 mm and the mixture is slowly warmed up to ambient temperature and stored at that temperature for 2 h The mixture is filtered through Cehte to remove the solid (NH4C.), and the filtrate is concentrated to obtain a crude cyclopropyisulfonamide solid (~ 1 2g) Re-cryslailization of the crude product from EtOAc/hexane produces cyclopropyisuifonarnide 42 in 80% overall yield.
7.03 g With ammonia; In tetrahydrofuran; for 16h; Cyclopropanesulfonamide A mixture of 50 ml of 25% aqueous ammonia solution and 50 ml of THF was initially charged, and then 10.00 g of cyclopropanesulfonyl chloride in 10 ml of THY were slowly added dropwise and the mixture was stirred for 16 hours. After concentration by rotary evaporation and coevaporation with toluene, the residue was extracted by stirring with 100 ml of ethyl acetate and the solids were filtered off. The organic phase was dried over Na2SO4 and concentrated by rotary evaporation. This gave the product (7.03 g) with a molecular weight of 121.2 g/mol (C3H7NO2S); MS (ESI): m/e=122 (M+H+).
7.03 g With ammonium hydroxide; In tetrahydrofuran; water; for 16h; Cyclopropanesulfonamide A mixture of 50 ml of 25% aqueous ammonia solution and 50 ml of THF was initially charged, and then 10.00 g of cyclopropanesulfonyl chloride in 10 ml of THF were slowly added dropwise and the mixture was stirred for 16 hours. After concentration by rotary evaporation and coevaporation with toluene, the residue was extracted by stirring with 100 ml of ethyl acetate and the solids were filtered off. The organic phase was dried over Na2SO4 and concentrated by rotary evaporation. This gave the product (7.03 g) with a molecular weight of 121.2 g/mol (C3H7NO2S); MS (ESI): m/e=122 (M+H+).
7.03 g In tetrahydrofuran; water; for 16h; A mixture of 50 ml of 25% aqueous ammonia solution and 50 ml of THF was initially charged, and then 10.00 g of cyclopropanesulfonyl chloride in 10 ml of THF were slowly added dropwise and the mixture was stirred for 16 hours. After concentration by rotary evaporation and coevaporation with toluene, the residue was extracted by stirring with 100 ml of ethyl acetate and the solids were filtered off. The organic phase was dried over Na2SO4 and concentrated by rotary evaporation. This gave the product (7.03 g) with a molecular weight of 121.2 g/mol (C3H7NO2S); MS (ESI): m/e=122 (M+H+).
With ammonia; In tetrahydrofuran; at 0 - 20℃; [0314] Ammonia gas was bubbled through a gas dispersion tube into THF (40 mL) cooled to 0 0C for 5 minutes. To this solution at 00C was added cyclopropylsulfonylchloride (1 gram, 7.1 mmol). The reaction was stirred at room temperature overnight, then filtered through a plug of silica gel, followed by elution with EtOAc to yield 750 mg (6.19 mmol) of cyclopropylsulfonamide. 1H-NMR (500 MHz, Methanol-d4): 4.79 (s, 2H), 2.59-2.54 (m, IH), 1.06-0.96 (m, 4H).

References: [1]Patent: US2006/183694,2006,A1 .Location in patent: Page/Page column 25.
[2]Patent: US2007/10455,2007,A1 .Location in patent: Page/Page column 26.
[3]Patent: US2008/14173,2008,A1 .Location in patent: Page/Page column 26.
[4]Patent: US2008/107625,2008,A1 .Location in patent: Page/Page column 24.
[5]Patent: WO2003/99274,2003,A1 .Location in patent: Page 65.
[6]Patent: US2004/77551,2004,A1 .Location in patent: Page/Page column 33.
[7]Patent: WO2005/51410,2005,A1 .Location in patent: Page/Page column 78.
[8]Patent: WO2008/64061,2008,A1 .Location in patent: Page/Page column 50.
[9]Patent: US2007/93414,2007,A1 .Location in patent: Page/Page column 39.
[10]Patent: US2007/99825,2007,A1 .Location in patent: Page/Page column 28.
[11]Patent: US2008/107623,2008,A1 .Location in patent: Page/Page column 23.
[12]Patent: US2008/107624,2008,A1 .Location in patent: Page/Page column 24.
[13]Patent: US2008/119461,2008,A1 .Location in patent: Page/Page column 23.
[14]Patent: WO2008/64057,2008,A1 .Location in patent: Page/Page column 48.
[15]Patent: WO2008/137779,2008,A2 .Location in patent: Page/Page column 212.
[16]Patent: US2008/32936,2008,A1 .Location in patent: Page/Page column 55.
[17]Patent: US2009/47252,2009,A1 .Location in patent: Page/Page column 33.
[18]Patent: WO2007/25307,2007,A2 .Location in patent: Page/Page column 292-293.
[19]Patent: US2007/299078,2007,A1 .Location in patent: Page/Page column 56.
[20]Patent: WO2008/19266,2008,A2 .Location in patent: Page/Page column 54.
[21]Patent: WO2008/19303,2008,A2 .Location in patent: Page/Page column 57.
[22]Patent: US2008/274080,2008,A1 .Location in patent: Page/Page column 29.
[23]Patent: WO2008/22006,2008,A2 .Location in patent: Page/Page column 50.
[24]Patent: WO2008/134397,2008,A1 .Location in patent: Page/Page column 42; 43.
[25]Patent: US2017/253569,2017,A1 .Location in patent: Paragraph 0054; 0401-0402.
[26]Patent: US2002/111313,2002,A1 .
[27]Patent: US2004/48802,2004,A1 .
[28]Patent: US2009/274648,2009,A1 .
[29]Patent: US2009/304626,2009,A1 .
[30]Patent: WO2010/34105,2010,A1 .Location in patent: Page/Page column 57-58.
[31]Patent: US2013/338150,2013,A1 .Location in patent: Paragraph 0282; 0283.
[32]Patent: US2014/24584,2014,A1 .Location in patent: Paragraph 0322; 0323.
[33]Patent: US2013/345125,2013,A1 .Location in patent: Paragraph 0225-0226.
[34]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 2267 - 2272.
[35]Patent: WO2008/106139,2008,A1 .Location in patent: Page/Page column 462.
[36]Chemical Communications,2020,vol. 56,p. 5010 - 5013.
  • 2
  • [ 475106-18-4 ]
  • [ 139631-62-2 ]
  • 3-(cyclopropanesulphonylamino-methyl)-morpholine-4-carboxylic acid tert-butyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In dichloromethane; at 0 - 20℃; for 1.5h; Example 19; The following representative example illustrates the synthesis of an amine educt in the morpholine series. Procedure for making an intermediate according to Scheme H. 3-(Cyclopropanesulphonylamino-methyl)-morpholine-4-carboxylic acid tert-butyl esterTo a solution of 21 mg (0.10 mmol) 3-Aminomethyl-morpholine-4-carboxylic acid tert-butyl ester (prepared according to Example 18, steps 1, 2 and 3) and 15 μL (0.12 mmol) of triethylamine in 3 mL of dichloromethane at 0 C. is added 15 mg (0.11 mmol) of cyclopropanesulphonyl chloride. After stirring for 1.5 h at room temperature dichloromethane is added. The organic solution is washed successively with a 5% aqueous citric acid solution, with a saturated aqueous sodium bicarbonate solution and with brine. After drying over sodium sulphate and evaporating the solvent under reduced pressure, the title compound, was obtained which was used crude in the next step without further purification.LC/MS (II) rt 2.26, m/z 384 [M+H+CH3CN]+.
  • 3
  • [ 269410-08-4 ]
  • [ 139631-62-2 ]
  • [ 1612172-62-9 ]
YieldReaction ConditionsOperation in experiment
50% With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 20℃; for 5h; To a solution of 4-pyrazoleboronic acid pinacol ester (1.02 g, 5.26 mmol) in DMF (15 mL) was added sodium hydride (60%, 0.32 g, 8 mmol) and cyclopropylsufonyl chloride (0.8 g, 5.78 mmol). The reaction was stirred at room temperature for 5 h. The mixture was then diluted with brine and extracted with EtOAc (3x). The combined extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (solvent gradient: 0-100%) EtOAc in heptane) to give the title compound(0.8 g, 50%).
50% With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 20℃; for 5h; To a solution of 4-pyrazoleboronic acid pinacol ester (1.02 g, 5.26 mmol) in NN- dimethylformamide (15 mL) was added sodium hydride (60 wt% dispersion in mineral oil)(0.32 g, 8 mmol) and cyclopropylsufonyl chloride (0.8 g, 5.78 mmol). The reaction was stirred at room temperature for 5 h. The mixture was then diluted with brine and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified via flash chromatography on silica gel (solvent gradient: 0%-100% EtOAc in heptane) to give l-(cyclopropylsulfonyl)-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (0.8 g, 50%).
49% To a stirred solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (1 g, 5.15 mmol) in DMF (15 mL) was added NaH (0.309 g, 7.73 mmol) and stirred for 5 min at room temperature. To the reaction mixture was addedcyclopropanesulfonyl chloride (0.797 g, 5.67 mmol) drop wise and stirred for 6 h at room temperature. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (20 mL) and extracted with ethyl acetate (2x50 mL). The combined organic extracts were washed with water (50 mL) and saturated brine solution (2x50 mL). The organic layer was then dried over anhydrous sodium sulfate, filtered andconcentrated under reduced pressure. The crude material was purified by flash column chromatography (Combiflash, 24 g silica, 0-80% EtO Ac/PE) to afford 1- (cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (750 mg, 2.52 mmol, 49 % yield) as a white solid. NMR (400 MHz, DMSO-d6) d 8.36 (s, 1H), 8.30 (s, 1H), 3.17-0.00 (m, 1H), 1.31-1.25 (m, 14H), 1.21-1.17 (m, 2H).
22% With sodium hydride; In N,N-dimethyl-formamide; at 20℃; for 24h;Inert atmosphere; Add 4- (4,4,5,5-tetramethyl-1,3,2-dioxolane-2-yl) -1H-pyrazole (3.0 g, 15 mmol), DMF (30 mL), NaH (0.62 g, 23 mmol) and cyclopropanesulfonyl chloride (2.4 g, 17 mmol) were replaced with nitrogen three times, and the reaction was stirred at room temperature for 24 h.Post-treatment: EA (50 mL) and water (50 mL) were added for dilution, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by silica gel column chromatography (PE / EA (V / V) = 1/1) purification to give the title compound as a white solid (1.0 g, 3.4 mmol, 22%).
22% In N,N-dimethyl-formamide; at 20℃; for 24h; 4- (4, 4, 5, 5-Tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazole (3.0 g, 15 mmol) , DMF (30 mL) , NaH (0.62 g, 23 mmol) and cyclopropanesulfonyl chloride (2.4 g, 17 mmol) were added to the single-necked bottle. The mixture was stirred at room temperature for 24 h, then diluted with EA (50 mL) and water (50 mL) . The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA (V/V) = 1/1) to give the title compound as a white solid (1.0 g, 3.4 mmol, 22%) . MS (ESI, pos. ion) m/z: 299.5 [M+H]+.
50 g Under the protection of nitrogen and room temperature, pyrazole-4-boronic acid pinacol ester 8-1 (50g, 257.7mmol) was dissolved in tetrahydrofuran (800mL), and then,Add sodium hydride (60%, 15.5 g, 387.5 mmol) to the above reaction solution at 0 C. and continue stirring at this temperature for 30 minutes;Then, cyclopropanesulfonyl chloride (43.3 g, 308 mmol) was slowly added dropwise to the above reaction solution at 0 C; the reaction solution was raised to room temperature and stirring continued for 16 hours. After LCMS monitoring showed that the starting material disappeared, water (7 mL) was added to the reaction solution for quenching. The resulting mixture was filtered, and the filter cake was washed with ethyl acetate (50 mL×3 times). The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=10/1) to obtain 50 g of compound 8-2

  • 4
  • [ 369-26-6 ]
  • [ 139631-62-2 ]
  • [ 1616809-47-2 ]
YieldReaction ConditionsOperation in experiment
With pyridine; dmap; at 110℃; for 12h; Methyl 3-amino-4-fluorobenzoate (275mg) and DMAP (100mg) were dissolved in pyridine (lOml). Then cyclopropanesulfonyl chloride (330mg) was added into the solution. The reaction mixture was heated to 110°C and stirred for 12 hours until the reaction is complete. The solvent was stripped off, the solid was dissolved in CH2C12 (50m1) followed by iN HC1 solution (50m1). The bottom aqueous layer was split off and the organic layer was washed with water and dried by anhydrous Na2SO4. The CH2C12 was stripped off and 270mg of methyl 3 -(cyclopropanesulfonamido)-4-fluorobenzoate was used for the next step directly.
  • 5
  • [ 139631-62-2 ]
  • [ 162167-97-7 ]
  • tert-butyl 3-(cyclopropanesulfonamidomethyl)piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In dichloromethane; at 20℃; for 2h; General procedure: To a stirred solution of 1.1 (2.0 g, 9.33 mmol) in CH2C12 (25 mL) were added (0805) Et3N (1.8 g, 18.66 mmol) and methane sulphonyl chloride (1.60 g, 13.99 mmol) at RT. The reaction mixture was stirred ate RT for 16h. Upon complete consumption of starting material, the reaction mixture was poured into water (50 mL), extracted with CH2C12 (2 x 50 mL). The organic extracts were washed with saturated NaHC03 (40 mL), water (40 mL), brine (40 mL), dried over anhydrous Na2S04 and concentrated under reduced pressure to afford 1.2 (2.0 g, crude) as a thick colorless liquid. MS (MM): m/z = 193.0 [M-Boc]+
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 139631-62-2 ]

Aliphatic Cyclic Hydrocarbons

Chemical Structure| 1220695-06-6

A513025 [1220695-06-6]

Cyclobutylmethanesulfonyl chloride

Similarity: 0.71

Sulfonyl Chlorides

Chemical Structure| 10147-36-1

A261628 [10147-36-1]

Propane-1-sulfonyl chloride

Similarity: 0.86

Chemical Structure| 10147-37-2

A385458 [10147-37-2]

2-Propanesulfonyl chloride

Similarity: 0.86

Chemical Structure| 35432-36-1

A433732 [35432-36-1]

2-Methylpropane-1-sulfonyl chloride

Similarity: 0.81

Chemical Structure| 594-44-5

A495132 [594-44-5]

Ethanesulfonyl chloride

Similarity: 0.72

Chemical Structure| 1220695-06-6

A513025 [1220695-06-6]

Cyclobutylmethanesulfonyl chloride

Similarity: 0.71

Chlorides

Chemical Structure| 10147-36-1

A261628 [10147-36-1]

Propane-1-sulfonyl chloride

Similarity: 0.86

Chemical Structure| 10147-37-2

A385458 [10147-37-2]

2-Propanesulfonyl chloride

Similarity: 0.86

Chemical Structure| 35432-36-1

A433732 [35432-36-1]

2-Methylpropane-1-sulfonyl chloride

Similarity: 0.81

Chemical Structure| 594-44-5

A495132 [594-44-5]

Ethanesulfonyl chloride

Similarity: 0.72

Chemical Structure| 1220695-06-6

A513025 [1220695-06-6]

Cyclobutylmethanesulfonyl chloride

Similarity: 0.71